ORAMED PHARMACEUTICALS INC. (ORMP) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-02

ORAMED PHARMACEUTICALS INC. (ORMP) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 1 Form 8-K material event filings were reported by ORMP in the last 90 days. 2 Form 144 notices of proposed sale were filed for ORMP stock. InsiderAlpha tracks every ORMP SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About ORAMED PHARMACEUTICALS INC. (ORMP)

SEC CIK	0001176309

90-Day SEC Filing Activity

Form 4 filings (90d)	2
Form 8-K filings (90d)	1
Form 144 notices (90d)	2
Latest Form 4 filing	2026-07-02

Recent ORMP Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-02	Hexter Joshua	COO & CBO	M — Option exercise	50.0K	$3.69	$184K	SEC
2026-07-01	Hexter Joshua	COO & CBO	S — Open-market sale	137.0K	$4.46	$611K	SEC
2026-07-01	Gabay Avraham	Chief Financial Officer	S — Open-market sale	73.4K	$4.51	$331K	SEC
2026-03-30	KIDRON NADAV	President and CEO	F — Tax withholding / forfeiture	44.8K	$3.31	$148K	SEC
2026-03-30	Kidron Miriam	Chief Scientific Officer	F — Tax withholding / forfeiture	435.1K	$3.31	$1.44M	SEC
2026-03-17	KIDRON NADAV	President and CEO	A — Grant or award	167.0K	$0.00	—	SEC
2026-03-17	Gabay Avraham	Chief Financial Officer	A — Grant or award	95.9K	$0.00	—	SEC
2026-03-17	Hexter Joshua	COO & CBO	A — Grant or award	95.9K	$0.00	—	SEC
2026-03-17	Kidron Miriam	Chief Scientific Officer	A — Grant or award	119.6K	$0.00	—	SEC
2026-03-12	KIDRON NADAV	President and CEO	G — Bona-fide gift	100.0K	$0.00	—	SEC
2026-01-22	Kidron Miriam	Chief Scientific Officer	M — Option exercise	19.0K	$0.00	—	SEC
2026-01-22	KIDRON NADAV	President and CEO	M — Option exercise	109.0K	$0.00	—	SEC
2026-01-22	Hexter Joshua	COO & CBO	M — Option exercise	19.0K	$0.00	—	SEC
2026-01-22	Gabay Avraham	Chief Financial Officer	M — Option exercise	19.0K	$0.00	—	SEC
2026-01-14	Kidron Miriam	Chief Scientific Officer	G — Bona-fide gift	86.2K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for ORAMED PHARMACEUTICALS INC. (ORMP). Updated in real time as new filings are submitted to the SEC.

Most-Active ORMP Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Hexter Joshua	3	$796K
Gabay Avraham	1	$331K

Recent ORMP Form 8-K Material Events

2026-06-30 — Item 5.03, 8.01, 9.01 [SEC]
2026-03-31 — Item 1.01, 2.01 · Acquisition · neutral [SEC]
Oramed Pharmaceuticals completed the sale of its wholly-owned subsidiary Oratech Pharma to Lifeward Ltd. on March 25, 2026, pursuant to a Share Purchase Agreement entered into on January 12, 2026. In consideration, Oramed received Lifeward ordinary shares, pre-funded warrants rep
2026-02-20 — Item 1.01, 9.01 · Contract · neutral [SEC]
Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company on February 19, 2026, whereby Oramed deferred a scheduled amortization payment in exchange for receiving warrants to purchase 100,000 shares of Scilex common stock at $20.00 per share, exercisable

Recent ORMP Form 144 Notices of Proposed Sale

2026-07-01 — — [SEC]
2026-07-01 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-07-02 — Hexter Joshua (COO & CBO)
2026-07-02 — Gabay Avraham (Chief Financial Officer)
2026-03-31 — KIDRON NADAV (President and CEO)
2026-03-31 — Kidron Miriam (Chief Scientific Officer)
2026-03-18 — Kidron Miriam (Chief Scientific Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ORMP insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ORMP Insider Trading — FAQ

What is the latest insider trade for ORMP?: ORAMED PHARMACEUTICALS INC. (ORMP) had 2 insider filings in the last 90 days, with the most recent on 2026-07-02. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ORMP stock?: 0 insider purchases of ORMP were filed in the last 90 days.
How many insiders are selling ORMP stock?: 0 insider sales of ORMP were filed in the last 90 days.
Where can I see ORMP SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ORMP SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ORMP dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.